Event Details
This disclosure is in furtherance to earlier intimations dated 12th August, 2025 and 13th February, 2026 regarding the Shareholders' Agreement for incorporation of this subsidiary.
Joint Venture Particulars
Target Entity Details
- Name: Alkem Pharma Company, Limited Liability Company ("Alkem Pharma")
- Capital: 7,500,000.0 SAR divided into 75,000.0 shares of 100 SAR each
- Turnover: Not Applicable (newly incorporated entity)
- Industry: Pharmaceuticals and Nutraceuticals
Transaction Structure
- Consideration Type: Cash consideration
- Investment Amount: Subscription of 38,250 Shares of 100 SAR each amounting to 3,825,000.00 SAR
- Shareholding Acquired: 51% of the total share capital of the Subsidiary
Business Operations
The Subsidiary will be involved in the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia.
Regulatory and Compliance Aspects
- Related Party Status: The acquisition does not fall under related party transaction
- Promoter Interest: None of the promoter/promoter group/group companies have any interest in the entity
- Government Approvals: Not Applicable
- Time Period for Completion: Not Applicable
Strategic Rationale
The investment in the Subsidiary is a strategic investment undertaken by the Company with the objective of expanding the Company's business and market reach to the Kingdom of Saudi Arabia.